Frequently Asked Questions about Telix Pharmaceuticals Limited (TLX)

Name: Telix Pharmaceuticals Limited (TLX) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Telix Pharmaceuticals Limited (TLX) do?

Accepted Answer

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix ...

Question 2

Is Telix Pharmaceuticals Limited (TLX) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of TLX reveals an Altman Z-Score of 3.60 and a Piotroski F-Score of 3/9. These metrics, combined with its 5-year revenue trend ($1.21B most recent), help investors decide if TLX fits their risk profile.

Question 3

What is the current P/E ratio for TLX?

Accepted Answer

As of the latest trading session, Telix Pharmaceuticals Limited (TLX) has a trailing P/E ratio of -423.70.

Question 4

Who is the CEO of Telix Pharmaceuticals Limited?

Accepted Answer

The current Chief Executive Officer of Telix Pharmaceuticals Limited is Christian Behrenbruch.

Question 5

What was TLX's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Telix Pharmaceuticals Limited reported annual revenues of $1.21B (2025), $0.78B (2024), $0.50B (2023), $0.16B (2022), $0.01B (2021) respectively.

Question 6

Does TLX pay a dividend?

Accepted Answer

Telix Pharmaceuticals Limited does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does TLX have?

Accepted Answer

In its latest reporting period, Telix Pharmaceuticals Limited generated $-0.08B in Free Cash Flow against a total debt load of $0.78B.

Question 8

What is the Price-to-Book (P/B) ratio of Telix Pharmaceuticals Limited?

Accepted Answer

The Price-to-Book (P/B) ratio for Telix Pharmaceuticals Limited (TLX) is currently 7.39.

Question 9

What is the Price-to-Sales (P/S) ratio of TLX?

Accepted Answer

Based on trailing twelve-month data, Telix Pharmaceuticals Limited (TLX) trades at a Price-to-Sales (P/S) ratio of 3.76.

Question 10

What is Telix Pharmaceuticals Limited's Return on Equity (ROE)?

Accepted Answer

Telix Pharmaceuticals Limited (TLX) has a Return on Equity (ROE) of -2.08%, representing its profitability relative to shareholder equity.

Period	Revenue	Gross Profit	Op. Income	Net Income	EPS
2025-12	1.2B	640.2M	26.6M	-10.7M	-0.03
2024-12	783.2M	509.7M	82.1M	49.9M	0.15
2023-12	502.5M	314.4M	51.9M	5.2M	0.02
2022-12	160.1M	29.3M	-91.9M	-104.1M	-0.34
2021-12	7.6M	-29.8M	-81.2M	-80.5M	-0.29

Period	Revenue	Gross Profit	Op. Income	Net Income	EPS
2025-12	1.2B	640.2M	26.6M	-10.7M	-0.03
2024-12	783.2M	509.7M	82.1M	49.9M	0.15
2023-12	502.5M	314.4M	51.9M	5.2M	0.02
2022-12	160.1M	29.3M	-91.9M	-104.1M	-0.34
2021-12	7.6M	-29.8M	-81.2M	-80.5M	-0.29